azd4205
Small moleculeexperimental
Clinical trial activity
8 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 16, 2018 (NCT03450330)
Timeline
Indications
Mechanism of action
- Jak1 proteinINHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06295432 | Phase 2 | Jun 1, 2023 | Dizal (Jiangsu) Pharmaceutical Co., Ltd., Shantou University |
| NCT05486949 | Phase 1 | Jul 27, 2022 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| NCT06511895 | Phase 2 | May 31, 2022 | Dizal (Jiangsu) Pharmaceutical Co., Ltd., Peking University |
| NCT06511869 | Phase 2 | Mar 17, 2022 | Dizal (Jiangsu) Pharmaceutical Co., Ltd., Zhejiang University |
| NCT04225208 | Phase 1 | Jan 31, 2020 | Dizal (Jiangsu) Pharmaceutical Co., Ltd., Pharmaron |
| NCT04105010 | Phase 1/Phase 2 (Phase 2) | Sep 10, 2019 | Dizal (Jiangsu) Pharmaceutical Co., Ltd., Sungkyunkwan University |
| NCT03728023 | Phase 1 | Nov 12, 2018 | Dizal (Jiangsu) Pharmaceutical Co., Ltd., Frontage Laboratories, Inc. |
| NCT03450330 | Phase 1/Phase 2 (Phase 2) | Apr 16, 2018 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dizal (Jiangsu) Pharmaceutical Co., Ltd. | For profit | 8 | 8 | 2 | 2018 |
| Frontage Laboratories, Inc. | For profit | 1 | 0 | 1 | 2018 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Pharmaron | For profit | 1 | 0 | 1 | 2020 |
| Shantou University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2022 |
7 organizations
Page 1 / 1